UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $164.67 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 15.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 2,284,231 shares of the medical equipment provider's stock after buying an additional 312,614 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 1.01% of Hologic worth $164,670,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Venturi Wealth Management LLC boosted its position in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC lifted its stake in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 260 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after acquiring an additional 159 shares during the period. Smithfield Trust Co grew its position in shares of Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 400 shares during the last quarter. Finally, Raiffeisen Bank International AG bought a new position in shares of Hologic during the fourth quarter worth about $49,000. 94.73% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Stephens reduced their target price on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Evercore ISI decreased their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Needham & Company LLC restated a "hold" rating on shares of Hologic in a research report on Friday, May 2nd. Finally, William Blair reaffirmed an "outperform" rating on shares of Hologic in a research note on Thursday, February 6th. Twelve analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $77.42.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus bought 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were bought at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the transaction, the director now directly owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.88% of the company's stock.

Hologic Price Performance

NASDAQ:HOLX traded down $0.20 during mid-day trading on Monday, reaching $54.28. 2,268,541 shares of the stock were exchanged, compared to its average volume of 2,144,938. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The business has a fifty day moving average price of $58.17 and a 200 day moving average price of $66.43. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67. The firm has a market capitalization of $12.10 billion, a PE ratio of 17.12, a PEG ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The business's revenue for the quarter was down 1.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.03 EPS. Research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.